Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 20/20 | 0.54 |
| ▸ | SOAT1 | P35610 | 14/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8992167 | 0.89 | DGAT1 (0.55) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL2126247 | 0.79 | DGAT1 (0.65) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL23339907 | 0.77 | DGAT1 (0.67) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL8992350 | 0.77 | DGAT1 (0.46) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL2124801 | 0.75 | DGAT1 (0.62) | DGAT1SOAT1 | |
| SCHEMBL5538632 | 0.75 | DGAT1 (0.77) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL8992151 | 0.75 | DGAT1 (0.47) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL5532585 | 0.74 | DGAT1 (0.72) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL5538724 | 0.72 | DGAT1 (0.60) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL2126583 | 0.72 | DGAT1 (0.60) | DGAT1SOAT1FAAHCHRM2DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-8188092-B2 | Substituted pyrazines as DGAT-1 inhibitors | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | GPBAR1, DGAT1, GPR119 | DGAT1 2/4885SOAT1 11/4885FAAH 829/4885 |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | DGAT1, DGAT2, SLC5A1 | DGAT1 1/4885SOAT1 9/4885FAAH 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.